Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Triamcinolone for Acne Vulgaris
NCT06170593Completed
- Sponsor
- ACON Laboratories
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of triamcinolone in acne vulgaris, sponsored by ACON Laboratories. Primary endpoint: Safety of intralesional triamcinolone injection at 14 days. Started Nov 2022; status: completed.
02
Drugs
triamcinolone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06170593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06170593.